Erlotinib U-03012 18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H

18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H

Formula: C7H15Cl2N2O2P

InChi: InChI=1S/C30H38N4

Chemical Name: 4-[(2S

Smiles: CC1(C)[C@@H]2CC[C@]3(C)[C@H](C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(O)=O)[C@@]2(C)CC[C@@H]1O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O

Erlotinib U-03012 18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5HErlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). Erlotinib HCl was approved. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the